Neurology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Fisher, M. A.
Right arrow Articles by Glass, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Fisher, M. A.
Right arrow Articles by Glass, S.

Neurology, Vol 48, Issue 5 1156-1160, Copyright © 1997 by American Academy of Neurology

ARTICLES

Butorphanol (Stadol): a study in problems of current drug information and control

MA Fisher and S Glass
Department of Neurology, Loyola University Chicago Medical Center, and the Hines Veterans Affairs Hospital, IL 60141, USA.

Butorphanol (Stadol, Bristol-Meyers Squibb, Princeton, NJ) is a synthetically derived opiate. As a nasal spray, it was approved for release in 1991 and was subsequently promoted as a safe treatment for migraine. Since then, there have been numerous reports of problems with butorphanol similar to those of any narcotic, especially dependence- addiction and major psychological disturbances. These problems have been documented by the Food and Drug Administration, but the information can be obtained only through the Freedom of Information Act. The experience with butorphanol indicates the need for physicians to have additional sources of information about drugs than are presently available.


This article has been cited by other articles:


Home page
 Am J Health Syst PharmHome page
G. A. Davis, A. C. Rudy, S. M. Archer, and D. P. Wermeling
Bioavailability of intranasal butorphanol administered from a single-dose sprayer
Am. J. Health Syst. Pharm., January 1, 2005; 62(1): 48 - 53.
[Abstract] [Full Text] [PDF]

Home page
 AM J HOSP PALLIAT CAREHome page
S. J. Baumrucker
OxyContin (R), the media, and law enforcement
American Journal of Hospice and Palliative Medicine, May 1, 2001; 18(3): 154 - 156.
[PDF]

Home page
 JAMAHome page
J. Streltzer, C. D. Donohoe, D. J. Murphy, and R. L. Portenoy
Pain Management and Chemical Dependency
JAMA, January 7, 1998; 279(1): 17 - 18.
[Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1997 by AAN Enterprises, Inc.